(19)
(11) EP 0 960 110 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.11.2002 Bulletin 2002/48

(45) Mention of the grant of the patent:
20.03.2002 Bulletin 2002/12

(21) Application number: 97954301.4

(22) Date of filing: 23.12.1997
(51) International Patent Classification (IPC)7: C07D 487/04, A61K 31/505
// (C07D487/04, 239:00, 231:00)
(86) International application number:
PCT/US9724/172
(87) International publication number:
WO 9802/9413 (09.07.1998 Gazette 1998/27)

(54)

3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS

3-ARYL PYRAZOLO[4,3-D]PYRIMIDIN DERIVATE; CORTICOTROPIN AUSLÖSEFAKTOR-REZEPTOR (CRF1) SPEZIFISCHE LIGANDEN

DERIVES DE PYRAZOLO[4,3-D]PYRIMIDINE A SUBSTITUTION ARYLE EN POSITION 3; LIGANDS SPECIFIQUES AU RECEPTEUR DE FACTEUR LIBERATEUR DE CORTICOTROPHINE (CRF1)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 31.12.1996 US 775404

(43) Date of publication of application:
01.12.1999 Bulletin 1999/48

(73) Proprietor: NEUROGEN CORPORATION
Branford, CT 06405 (US)

(72) Inventor:
  • YUAN, Jun
    Guilford, CT 06437 (US)

(74) Representative: Vossius, Volker, Dr. et al
Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Geibelstrasse 6
81679 München
81679 München (DE)


(56) References cited: : 
EP-A- 0 691 128
WO-A-95/33750
WO-A-97/29109
 WO-A-94/13677
WO-A-96/35689
   
  • H TAKEI ET AL: "A new synthetic method for some Pyrazolo[4,3-d]pyrimidines" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 52, no. 1, 1979, TOKYO, pages 208-211, XP002062574 cited in the application
  • J AVILA ET AL: "Biological action of pyrazolopyrimidine derivatives against Trypanosoma cruzi" COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C, COMPARATIVE PHARMACOLOGY AND TOXICOLOGY , vol. 74, no. 1, 1993, LONDON, pages 49-54, XP002062575
  • M J OWENS ET AL: "Physiology and pharmacology of Corticotropin-releasing factor" PHARMACOLOGICAL REVIEWS, vol. 43, no. 4, 1991, USA, pages 425-473, XP000614410
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).